Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Buy
57
PBH Quote, Financials, Valuation and Earnings
Last price:
$61.19
Seasonality move
:
4.54%
Day range:
$61.34 - $62.40
52-week range:
$57.25 - $90.04
Dividend yield:
0%
P/E ratio:
15.30x
P/S ratio:
2.77x
P/B ratio:
1.63x
Volume:
264K
Avg. volume:
438.4K
1-year change:
-21%
Market cap:
$3B
Revenue:
$1.1B
EPS (TTM):
$4.03
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
PBH
Prestige Consumer Healthcare, Inc.
|
$286.9M | $1.18 | -1.17% | -3.69% | $78.00 |
|
ABT
Abbott Laboratories
|
$11.8B | $1.50 | 7.51% | -71.7% | $144.43 |
|
MYO
Myomo, Inc.
|
$10.4M | -$0.09 | -13.8% | -1168.66% | $5.00 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
OSUR
OraSure Technologies, Inc.
|
$26.4M | -$0.15 | -29.38% | -5.2% | $4.50 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
PBH
Prestige Consumer Healthcare, Inc.
|
$61.69 | $78.00 | $3B | 15.30x | $0.00 | 0% | 2.77x |
|
ABT
Abbott Laboratories
|
$125.29 | $144.43 | $217.9B | 15.72x | $0.59 | 1.88% | 5.00x |
|
MYO
Myomo, Inc.
|
$0.91 | $5.00 | $35M | -- | $0.00 | 0% | 0.90x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$5.64 | $0.85 | $710.7M | 9.47x | $0.80 | 0% | 10.96x |
|
OSUR
OraSure Technologies, Inc.
|
$2.42 | $4.50 | $173.6M | 26.67x | $0.00 | 0% | 1.43x |
|
PTN
Palatin Technologies
|
$0.09 | -- | $2.4M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
PBH
Prestige Consumer Healthcare, Inc.
|
36.32% | -0.562 | 34.7% | 2.50x |
|
ABT
Abbott Laboratories
|
20.25% | 0.321 | 5.99% | 1.12x |
|
MYO
Myomo, Inc.
|
45.68% | -2.417 | 35.87% | 1.94x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | -3.190 | 8.08% | 1.85x |
|
OSUR
OraSure Technologies, Inc.
|
3.59% | 0.867 | 5.8% | 5.99x |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
PBH
Prestige Consumer Healthcare, Inc.
|
$146.4M | $79.7M | 7.05% | 11.11% | 29.07% | $55.4M |
|
ABT
Abbott Laboratories
|
$5.9B | $2.2B | 22.49% | 29.06% | 19.03% | $2.3B |
|
MYO
Myomo, Inc.
|
$6.4M | -$3.5M | -46.49% | -68.35% | -34.86% | -$2.9M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
OSUR
OraSure Technologies, Inc.
|
$10.4M | -$15.7M | -14.75% | -15.25% | -58.02% | -$11M |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
Prestige Consumer Healthcare, Inc. vs. Competitors
-
Which has Higher Returns PBH or ABT?
Abbott Laboratories has a net margin of 15.4% compared to Prestige Consumer Healthcare, Inc.'s net margin of 14.07%. Prestige Consumer Healthcare, Inc.'s return on equity of 11.11% beat Abbott Laboratories's return on equity of 29.06%.
Company Gross Margin Earnings Per Share Invested Capital PBHPrestige Consumer Healthcare, Inc.53.41% $0.86 $2.9B ABTAbbott Laboratories52.05% $0.91 $64.2B -
What do Analysts Say About PBH or ABT?
Prestige Consumer Healthcare, Inc. has a consensus price target of $78.00, signalling upside risk potential of 26.44%. On the other hand Abbott Laboratories has an analysts' consensus of $144.43 which suggests that it could grow by 15.28%. Given that Prestige Consumer Healthcare, Inc. has higher upside potential than Abbott Laboratories, analysts believe Prestige Consumer Healthcare, Inc. is more attractive than Abbott Laboratories.
Company Buy Ratings Hold Ratings Sell Ratings PBHPrestige Consumer Healthcare, Inc.5 1 0 ABTAbbott Laboratories15 7 0 -
Is PBH or ABT More Risky?
Prestige Consumer Healthcare, Inc. has a beta of 0.396, which suggesting that the stock is 60.435% less volatile than S&P 500. In comparison Abbott Laboratories has a beta of 0.721, suggesting its less volatile than the S&P 500 by 27.854%.
-
Which is a Better Dividend Stock PBH or ABT?
Prestige Consumer Healthcare, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Abbott Laboratories offers a yield of 1.88% to investors and pays a quarterly dividend of $0.59 per share. Prestige Consumer Healthcare, Inc. pays -- of its earnings as a dividend. Abbott Laboratories pays out 29.33% of its earnings as a dividend. Abbott Laboratories's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios PBH or ABT?
Prestige Consumer Healthcare, Inc. quarterly revenues are $274.1M, which are smaller than Abbott Laboratories quarterly revenues of $11.4B. Prestige Consumer Healthcare, Inc.'s net income of $42.2M is lower than Abbott Laboratories's net income of $1.6B. Notably, Prestige Consumer Healthcare, Inc.'s price-to-earnings ratio is 15.30x while Abbott Laboratories's PE ratio is 15.72x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Prestige Consumer Healthcare, Inc. is 2.77x versus 5.00x for Abbott Laboratories. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PBHPrestige Consumer Healthcare, Inc.2.77x 15.30x $274.1M $42.2M ABTAbbott Laboratories5.00x 15.72x $11.4B $1.6B
-
Which has Higher Returns PBH or MYO?
Myomo, Inc. has a net margin of 15.4% compared to Prestige Consumer Healthcare, Inc.'s net margin of -36.3%. Prestige Consumer Healthcare, Inc.'s return on equity of 11.11% beat Myomo, Inc.'s return on equity of -68.35%.
Company Gross Margin Earnings Per Share Invested Capital PBHPrestige Consumer Healthcare, Inc.53.41% $0.86 $2.9B MYOMyomo, Inc.63.84% -$0.09 $26.9M -
What do Analysts Say About PBH or MYO?
Prestige Consumer Healthcare, Inc. has a consensus price target of $78.00, signalling upside risk potential of 26.44%. On the other hand Myomo, Inc. has an analysts' consensus of $5.00 which suggests that it could grow by 449.45%. Given that Myomo, Inc. has higher upside potential than Prestige Consumer Healthcare, Inc., analysts believe Myomo, Inc. is more attractive than Prestige Consumer Healthcare, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PBHPrestige Consumer Healthcare, Inc.5 1 0 MYOMyomo, Inc.4 0 0 -
Is PBH or MYO More Risky?
Prestige Consumer Healthcare, Inc. has a beta of 0.396, which suggesting that the stock is 60.435% less volatile than S&P 500. In comparison Myomo, Inc. has a beta of 1.052, suggesting its more volatile than the S&P 500 by 5.158%.
-
Which is a Better Dividend Stock PBH or MYO?
Prestige Consumer Healthcare, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Prestige Consumer Healthcare, Inc. pays -- of its earnings as a dividend. Myomo, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PBH or MYO?
Prestige Consumer Healthcare, Inc. quarterly revenues are $274.1M, which are larger than Myomo, Inc. quarterly revenues of $10.1M. Prestige Consumer Healthcare, Inc.'s net income of $42.2M is higher than Myomo, Inc.'s net income of -$3.7M. Notably, Prestige Consumer Healthcare, Inc.'s price-to-earnings ratio is 15.30x while Myomo, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Prestige Consumer Healthcare, Inc. is 2.77x versus 0.90x for Myomo, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PBHPrestige Consumer Healthcare, Inc.2.77x 15.30x $274.1M $42.2M MYOMyomo, Inc.0.90x -- $10.1M -$3.7M
-
Which has Higher Returns PBH or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of 15.4% compared to Prestige Consumer Healthcare, Inc.'s net margin of -255.85%. Prestige Consumer Healthcare, Inc.'s return on equity of 11.11% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital PBHPrestige Consumer Healthcare, Inc.53.41% $0.86 $2.9B NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About PBH or NBY?
Prestige Consumer Healthcare, Inc. has a consensus price target of $78.00, signalling upside risk potential of 26.44%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -84.93%. Given that Prestige Consumer Healthcare, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Prestige Consumer Healthcare, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PBHPrestige Consumer Healthcare, Inc.5 1 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is PBH or NBY More Risky?
Prestige Consumer Healthcare, Inc. has a beta of 0.396, which suggesting that the stock is 60.435% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.093, suggesting its less volatile than the S&P 500 by 90.725%.
-
Which is a Better Dividend Stock PBH or NBY?
Prestige Consumer Healthcare, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Prestige Consumer Healthcare, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PBH or NBY?
Prestige Consumer Healthcare, Inc. quarterly revenues are $274.1M, which are larger than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Prestige Consumer Healthcare, Inc.'s net income of $42.2M is higher than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Prestige Consumer Healthcare, Inc.'s price-to-earnings ratio is 15.30x while NovaBay Pharmaceuticals, Inc.'s PE ratio is 9.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Prestige Consumer Healthcare, Inc. is 2.77x versus 10.96x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PBHPrestige Consumer Healthcare, Inc.2.77x 15.30x $274.1M $42.2M NBYNovaBay Pharmaceuticals, Inc.10.96x 9.47x $521K -$1.3M
-
Which has Higher Returns PBH or OSUR?
OraSure Technologies, Inc. has a net margin of 15.4% compared to Prestige Consumer Healthcare, Inc.'s net margin of -50.63%. Prestige Consumer Healthcare, Inc.'s return on equity of 11.11% beat OraSure Technologies, Inc.'s return on equity of -15.25%.
Company Gross Margin Earnings Per Share Invested Capital PBHPrestige Consumer Healthcare, Inc.53.41% $0.86 $2.9B OSUROraSure Technologies, Inc.38.29% -$0.19 $375.4M -
What do Analysts Say About PBH or OSUR?
Prestige Consumer Healthcare, Inc. has a consensus price target of $78.00, signalling upside risk potential of 26.44%. On the other hand OraSure Technologies, Inc. has an analysts' consensus of $4.50 which suggests that it could grow by 85.95%. Given that OraSure Technologies, Inc. has higher upside potential than Prestige Consumer Healthcare, Inc., analysts believe OraSure Technologies, Inc. is more attractive than Prestige Consumer Healthcare, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PBHPrestige Consumer Healthcare, Inc.5 1 0 OSUROraSure Technologies, Inc.1 2 0 -
Is PBH or OSUR More Risky?
Prestige Consumer Healthcare, Inc. has a beta of 0.396, which suggesting that the stock is 60.435% less volatile than S&P 500. In comparison OraSure Technologies, Inc. has a beta of 0.771, suggesting its less volatile than the S&P 500 by 22.858%.
-
Which is a Better Dividend Stock PBH or OSUR?
Prestige Consumer Healthcare, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. OraSure Technologies, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Prestige Consumer Healthcare, Inc. pays -- of its earnings as a dividend. OraSure Technologies, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PBH or OSUR?
Prestige Consumer Healthcare, Inc. quarterly revenues are $274.1M, which are larger than OraSure Technologies, Inc. quarterly revenues of $27.1M. Prestige Consumer Healthcare, Inc.'s net income of $42.2M is higher than OraSure Technologies, Inc.'s net income of -$13.7M. Notably, Prestige Consumer Healthcare, Inc.'s price-to-earnings ratio is 15.30x while OraSure Technologies, Inc.'s PE ratio is 26.67x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Prestige Consumer Healthcare, Inc. is 2.77x versus 1.43x for OraSure Technologies, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PBHPrestige Consumer Healthcare, Inc.2.77x 15.30x $274.1M $42.2M OSUROraSure Technologies, Inc.1.43x 26.67x $27.1M -$13.7M
-
Which has Higher Returns PBH or PTN?
Palatin Technologies has a net margin of 15.4% compared to Prestige Consumer Healthcare, Inc.'s net margin of --. Prestige Consumer Healthcare, Inc.'s return on equity of 11.11% beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PBHPrestige Consumer Healthcare, Inc.53.41% $0.86 $2.9B PTNPalatin Technologies-- -- -- -
What do Analysts Say About PBH or PTN?
Prestige Consumer Healthcare, Inc. has a consensus price target of $78.00, signalling upside risk potential of 26.44%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Prestige Consumer Healthcare, Inc., analysts believe Palatin Technologies is more attractive than Prestige Consumer Healthcare, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PBHPrestige Consumer Healthcare, Inc.5 1 0 PTNPalatin Technologies0 0 0 -
Is PBH or PTN More Risky?
Prestige Consumer Healthcare, Inc. has a beta of 0.396, which suggesting that the stock is 60.435% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
-
Which is a Better Dividend Stock PBH or PTN?
Prestige Consumer Healthcare, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Prestige Consumer Healthcare, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PBH or PTN?
Prestige Consumer Healthcare, Inc. quarterly revenues are $274.1M, which are larger than Palatin Technologies quarterly revenues of --. Prestige Consumer Healthcare, Inc.'s net income of $42.2M is higher than Palatin Technologies's net income of --. Notably, Prestige Consumer Healthcare, Inc.'s price-to-earnings ratio is 15.30x while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Prestige Consumer Healthcare, Inc. is 2.77x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PBHPrestige Consumer Healthcare, Inc.2.77x 15.30x $274.1M $42.2M PTNPalatin Technologies-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Sell
30
CORT alert for Jan 2
Corcept Therapeutics, Inc. [CORT] is up 5.4% over the past day.
Buy
75
AXSM alert for Jan 2
Axsome Therapeutics, Inc. [AXSM] is down 3.78% over the past day.
Sell
50
NUTX alert for Jan 2
Nutex Health, Inc. [NUTX] is down 8.96% over the past day.
